CONTEXT: Chromosomal fragile sites are often related to cancer development. The WW domain-containing oxidoreductase gene (WWOX) spans the second most common chromosomal fragile site (FRA16D) and encodes an important proapoptotic protein. OBJECTIVE: To verify our hypothesis that underexpression of WWOX could contribute to malignant transformation of the thyroid cells. METHOD: We compared WWOX expression among follicular adenomas (FAs) and differentiated thyroid carcinomas [follicular thyroid carcinomas (FTCs) and papillary thyroid carcinomas (PTCs)] in 53 thyroid tumors resected from patients submitted to total thyroidectomy. DESIGN: Multiple fields of tumor areas of FAs, FTCs, and PTCs as well as normal thyroid tissue were stained with WWOX antiserum, and classified by the extent of staining (percentage of cells staining) and staining intensity. MAIN OUTCOME: PTCs showed a significantly decreased expression of WWOX when compared to FAs and FTCs. Further, using a unique model of comparison in patients in whom FAs and PTCs were concomitantly present, we detected the same result (i.e., no expression in PTCs). CONCLUSION: We conclude that WWOX underexpression is an important step that might increase the vulnerability to the carcinogenesis process in PTCs.
CONTEXT: Chromosomal fragile sites are often related to cancer development. The WW domain-containing oxidoreductase gene (WWOX) spans the second most common chromosomal fragile site (FRA16D) and encodes an important proapoptotic protein. OBJECTIVE: To verify our hypothesis that underexpression of WWOX could contribute to malignant transformation of the thyroid cells. METHOD: We compared WWOX expression among follicular adenomas (FAs) and differentiated thyroid carcinomas [follicular thyroid carcinomas (FTCs) and papillary thyroid carcinomas (PTCs)] in 53 thyroid tumors resected from patients submitted to total thyroidectomy. DESIGN: Multiple fields of tumor areas of FAs, FTCs, and PTCs as well as normal thyroid tissue were stained with WWOX antiserum, and classified by the extent of staining (percentage of cells staining) and staining intensity. MAIN OUTCOME: PTCs showed a significantly decreased expression of WWOX when compared to FAs and FTCs. Further, using a unique model of comparison in patients in whom FAs and PTCs were concomitantly present, we detected the same result (i.e., no expression in PTCs). CONCLUSION: We conclude that WWOX underexpression is an important step that might increase the vulnerability to the carcinogenesis process in PTCs.
Authors: Flávio J Pimenta; Dawidson A Gomes; Paolla F Perdigão; Alvimar A Barbosa; Marco A Romano-Silva; Marcus V Gomez; C Marcelo Aldaz; Luiz De Marco; Ricardo S Gomez Journal: Int J Cancer Date: 2006-03-01 Impact factor: 7.396
Authors: Gulnur Guler; Aysegul Uner; Nilufer Guler; Shuang-Yin Han; Dimitrios Iliopoulos; Walter W Hauck; Peter McCue; Kay Huebner Journal: Cancer Date: 2004-04-15 Impact factor: 6.860
Authors: Rami I Aqeilan; Francesco Trapasso; Sadiq Hussain; Stefan Costinean; Dean Marshall; Yuri Pekarsky; John P Hagan; Nicola Zanesi; Mohamed Kaou; Gary S Stein; Jane B Lian; Carlo M Croce Journal: Proc Natl Acad Sci U S A Date: 2007-02-27 Impact factor: 11.205
Authors: María I Nunez; Daniel G Rosen; John H Ludes-Meyers; Martín C Abba; Hyunsuk Kil; Robert Page; Andres J P Klein-Szanto; Andrew K Godwin; Jinsong Liu; Gordon B Mills; C Marcelo Aldaz Journal: BMC Cancer Date: 2005-06-27 Impact factor: 4.430
Authors: Ileana Aderca; Catherine D Moser; Manivannan Veerasamy; Ahmad H Bani-Hani; Ruben Bonilla-Guerrero; Kadra Ahmed; Abdirashid Shire; Sophie C Cazanave; Damian P Montoya; Teresa A Mettler; Lawrence J Burgart; David M Nagorney; Stephen N Thibodeau; Julie M Cunningham; Jin-Ping Lai; Lewis R Roberts Journal: J Hepatol Date: 2008-06-09 Impact factor: 25.083